Alkem Laboratories Unveils 'Perjio': A Landmark Leap in Affordable Breast Cancer Treatment in India

In a monumental stride towards enhancing healthcare accessibility in India, Alkem Laboratories Ltd. has proudly announced the launch of 'Perjio', a groundbreaking biosimilar of Pertuzumab. This significant introduction marks Alkem as the pioneer Indian pharmaceutical company to bring a biosimilar version of this critical drug to market, offering a beacon of hope for patients battling HER2-positive early and metastatic breast cancer.

Pertuzumab, a targeted therapy, plays a pivotal role in the treatment regimen for this aggressive form of breast cancer.

Traditionally, the cost of innovator drugs has posed a substantial barrier to access for many patients in India. Alkem's 'Perjio' shatters this barrier by being priced at an incredibly accessible Rs 39,500 per 440mg vial. This pricing strategy represents a drastic reduction compared to the innovator drug, making advanced, life-saving treatment far more attainable for a larger segment of the population.

The launch of 'Perjio' is the culmination of meticulous research and development, a collaboration between Alkem and a leading global biosimilar company.

This partnership underscores Alkem's commitment to leveraging global expertise to address local healthcare needs effectively. Pertuzumab is typically administered in combination with Trastuzumab and chemotherapy, forming a robust therapeutic approach that has significantly improved patient outcomes.

Alkem's initiative is not merely about introducing a new drug; it's about revolutionizing the landscape of breast cancer care in India.

By making such a vital treatment more affordable, 'Perjio' has the potential to dramatically increase the number of patients who can access optimal therapy, leading to better prognosis and improved quality of life. This launch solidifies Alkem's position as a frontrunner in providing innovative and accessible healthcare solutions, reinforcing its dedication to patient welfare across the nation.